The Renin-Angiotensin System and Vascular Disease in Diabetes

Jaap Deinum; Nishi Chaturvedi

doi:10.1055/s-2002-32038

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2002; 2(2): 149-156
DOI: 10.1055/s-2002-32038

The Renin-Angiotensin System and Vascular Disease in Diabetes

Jaap Deinum¹ , Nishi Chaturvedi²

¹Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
²Department of Epidemiology and Public Health, Imperial College of Medicine at St. Mary's, London, England

Abstract

ABSTRACT

Angiotensin II, the effector molecule of the renin-angiotensin system, has profound effects on endothelial and smooth muscle cells. These effects are not only hemodynamic in nature, but also comprise inflammation, thrombosis, and cell proliferation through stimulation of production of cytokines and growth factors. In diabetes mellitus these effects seem amplified with adverse consequences like atherosclerosis and occlusive microangiopathy. Suggestive evidence for this notion is the impressive beneficial effect of pharmacological interference with the renin-angiotensin system in large vessel disease as well as in renal and retinal microangiopathy. Since the circulating renin-angiotensin system does not seem to be activated in diabetes mellitus it is now thought that independent tissue renin-angiotensin systems play a role in diabetic complications. Whether any genetic propensity to diabetic angiopathy resides in genes of the renin-angiotensin system remains to be determined.

KEYWORDS

Renin - angiotensin - diabetes - vascular disease

Full Text

References

REFERENCES

1 Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ (Clin Res Ed) . 1987; 294 1651-1654
2 Fuller J H, Head J. Blood pressure, proteinuria and their relationship with circulatory mortality: the WHO Multinational Study of Vascular Disease in Diabetics. Diabete Metab . 1989; 15 273-277
3 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet . 2000; 355 253-259
4 Chaturvedi N, Sjolie A K, Stephenson J M. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet . 1998; 351 28-31
5 United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. U.K. Prospective Diabetes Study Group. BMJ . 1998; 317 713-720
6 Ravid M, Lang R, Rachmani R. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med . 1996; 156 286-289
7 Toffelmire E B, Slater K, Corvol P. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay. J Clin Invest . 1989; 83 679-687
8 Hsueh W A, Baxter J D. Human prorenin. Hypertension . 1991; 17 469-477
9 Deinum J, Derkx F H, Schalekamp M A. Probing epitopes on human prorenin during its proteolytic and non-proteolytic activation. Biochim Biophys Acta . 1998; 10 386-396
10 Itoh H, Mukoyama M, Pratt R E. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest . 1993; 91 2268-2274
11 Pueyo M E, Michel J B. Angiotensin II receptors in endothelial cells. Gen Pharmacol . 1997; 29 691-696
12 Berk B C. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Soc Nephrol . 1999; S62-68 (S62-68)
13 Horiuchi M, Akishita M, Dzau V J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension . 1999; 33 613-621
14 Burns K D. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis . 2000; 36 449-467
15 Admiraal P J, Derkx F H, Danser A H. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension . 1990; 15 44-55
16 Deschepper C F, Mellon S H, Cumin F. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc Natl Acad Sci USA . 1986; 83 7552-7556
17 Danser A H, Admiraal P J, Derkx F H. Cardiac renin is kidney-derived. J Hypertens Suppl . 1993; S224-S225 (S224-S225)
18 Admiraal P J, van Kesteren A C, Danser A H. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens . 1999; 17 621-629
19 Morganti A, Pelizzola D, Mantero F. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. Italian Multicenter Study for Standardization of Renin Measurement. J Hypertens . 1995; 13 19-26
20 Bjorck S. The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study. Scand J Urol Nephrol Suppl . 1990; 126 1-51
21 Luetscher J A, Kraemer F B, Wilson D M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med . 1985; 312 1412-1417
22 Franken A A, Derkx F H, Man in't Veld J A. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab . 1990; 71 1008-1015
23 Deinum J, Ronn B, Mathiesen E. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia . 1999; 42 1006-1010
24 Seikaly M G, Arant Jr S B, Seney Jr D F. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest . 1990; 86 1352-1357
25 Gilbert R E, Cooper M E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int . 1999; 56 1627-1637
26 Metzger R, Bohle R M, Pauls K. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int . 1999; 56 1442-1454
27 Lai K N, Leung J C, Lai K B. Gene expression of the renin-angiotensin system in human kidney. J Hypertens . 1998; 16 91-102
28 Price D A, Porter L E, Gordon M. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol . 1999; 10 2382-2391
29 Singh R, Alavi N, Singh A K. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes . 1999; 48 2066-2073
30 Kelly D J, Wilkinson-Berka J L, Allen T J. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int . 1998; 54 343-352
31 Campbell D J, Kelly D J, Wilkinson-Berka J L. Increased bradykinin and ``normal'' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int . 1999; 56 211-221
32 Sramek S J, Wallow I H, Tewksbury D A. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci . 1992; 33 1627-1632
33 Wagner J, Jan Danser H A, Derkx F H. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol . 1996; 80 159-163
34 Berka J L, Stubbs A J, Wang D Z. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci . 1995; 36 1450-1458
35 Danser A H, van den Dorpel A M, Deinum J. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab . 1989; 68 160-167
36 Le Noble A F, Hekking J W, Van Straaten W H. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol . 1991; 195 305-306
37 Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy?. Miner Electrolyte Metab . 1998; 24 400-405
38 Lewis E J, Hunsicker L G, Bain R P. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med . 1993; 329 1456-1462
39 The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors?. <~>A meta-analysis of individual patient data. Ann Intern Med . 2001; 134 370-379
40 The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet . 1997; 349 1787-1792
41 Bohlen L SM, De Courten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. In: Mogensin CE, ed. The Kidney and Hypertension in Diabetes Mellitus 3rd ed. London: Kluwer Academic Publishers; 1997
42 United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. U.K. Prospective Diabetes Study Group. BMJ . 1998; 317 703-713
43 Mogensen C E, Neldam S, Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ . 2000; 321 1440-1444
44 Chan J C, Critchley J A, Tomlinson B. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol . 1997; 17 72-80
45 Adler A I, Stratton I M, Neil H A. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ . 2000; 321 412-419
46 Endlich K, Muller C, Barthelmebs M. Role of shear stress in nitric oxide-dependent modulation of renal angiotensin II vasoconstriction. Br J Pharmacol . 1999; 127 1929-1935
47 Prasad A, Tupas-Habib T, Schenke W H. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation . 2000; 101 2349-2354
48 Bech J N, Svendsen K B, Nielsen C B. The systemic and renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans. Nephrol Dial Transplant . 1999; 14 641-647
49 Zusman R M. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis . 1987; 10(1 suppl 1) 13-23
50 Williams B, Baker A Q, Gallacher B. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension . 1995; 25 913-917
51 Rosenberg G A, Kornfeld M, Estrada E. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res . 1992; 576 203-207
52 Lovett D H, Johnson R J, Marti H P. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol . 1992; 141 85-98
53 Ebihara I, Nakamura T, Shimada N. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis . 1998; 32 544-550
54 Sorbi D, Fadly M, Hicks R. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int . 1993; 44 1266-1272
55 Funakoshi Y, Ichiki T, Ito K. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension . 1999; 34 118-125
56 Sun Y, Zhang J, Zhang J Q. Local angiotensin II and transforming growth factor-β1 in renal fibrosis of rats. Hypertension . 2000; 35 1078-1084
57 Pueyo M E, Gonzalez W, Nicoletti A. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol . 2000; 20 645-651
58 Andersen S, Schalkwijk C G, Stehouwer C D. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care . 2000; 23 1031-1032
59 Rossing P, Rossing K, Jacobsen P. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes . 1995; 44 739-743
60 Quinn M, Angelico M C, Warram J H. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia . 1996; 39 940-945
61 Marre M, Bernadet P, Gallois Y. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes . 1994; 43 384-388
62 Tarnow L, Cambien F, Rossing P. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes . 1995; 44 489-494
63 Doria A, Warram J H, Krolewski A S. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes . 1994; 43 690-695
64 Chowdhury T A, Dronsfield M J, Kumar S. Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia . 1996; 39 1108-1114
65 Schmidt S, Schone N, Ritz E. Association of ACE gene polymorphism and diabetic nephropathy?. <~>The Diabetic Nephropathy Study Group. Kidney Int . 1995; 47 1176-1181
66 Penno G, Chaturvedi N, Talmud P J. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes . 1998; 47 1507-1511
67 Deinum J, Tarnow L, van Gool M J. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant . 1999; 14 1904-1911
68 Tarnow L, Cambien F, Rossing P. Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. Nephrol Dial Transplant . 1996; 11 1019-1023
69 Tarnow L, Cambien F, Rossing P. Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes . 1996; 45 367-369
70 Doria A, Onuma T, Warram J H. Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM. Diabetologia . 1997; 40 1293-1299
71 Tarnow L, Kjeld T, Knudsen E. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients. Diabetologia . 2000; 43 794-799